Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
NCT ID: NCT02647853
Last Updated: 2016-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2014-10-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds
NCT02607670
Safety and Performance of PTMC Dermal Filler
NCT06316479
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01124565
Safety Study of TPX-121 on Nasolabial Folds
NCT06533540
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01124552
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAT4 Gel concentration A
TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
TAT4 Gel concentration A
TAT4 Gel concentration B
TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
TAT4 Gel concentration B
Placebo
Placebo product once daily to 50 cm2 for 14 days.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAT4 Gel concentration A
TAT4 Gel concentration B
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy volunteers
* Provision of informed consent
Exclusion Criteria
* Abnormality on screening assessments
40 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Topokine Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Topokine Clinical Site
Cypress, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAT4 A1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.